CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of CEL-SCI (NYSE:CVM) in a research report released on Saturday morning. The firm issued a sell rating on the stock.

CEL-SCI Stock Performance

NYSE CVM opened at $0.24 on Friday. The business’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.62. The company has a current ratio of 1.07, a quick ratio of 1.09 and a debt-to-equity ratio of 0.66. CEL-SCI has a twelve month low of $0.23 and a twelve month high of $2.39. The company has a market capitalization of $19.12 million, a PE ratio of -0.50 and a beta of 0.67.

Hedge Funds Weigh In On CEL-SCI

Large investors have recently bought and sold shares of the stock. Thoroughbred Financial Services LLC grew its stake in shares of CEL-SCI by 40.1% during the 4th quarter. Thoroughbred Financial Services LLC now owns 191,661 shares of the company’s stock valued at $76,000 after buying an additional 54,900 shares during the period. Plotkin Financial Advisors LLC acquired a new position in CEL-SCI in the third quarter valued at $98,000. Finally, Geode Capital Management LLC grew its position in CEL-SCI by 9.6% during the third quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after acquiring an additional 53,879 shares during the period. Hedge funds and other institutional investors own 12.08% of the company’s stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.